Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2015

View Archived Issues

DiamiR receives funding to evaluate microRNA biomarkers for Alzheimer's disease

Sirtex reports preliminary data from the SIRFLOX study

Targazyme and M.D. Anderson Cancer Center to conduct study of TZ-101-treated T Cells

AstraZeneca reports phase III topline results for PT-003

FDA orphan drug designations for two IPF drugs

Universitaet zu Koeln divulges anti-CD30 CAR T cells

Non-toxic mitochondrial protonophore formulation shows potential for T2D and NAFLD/NASH

ALN-TTRSC has clinical activity in TTR cardiac amyloidosis patients

Full results presented from phase III ANNEXA-R study of andexanet alfa

BR-297: a neuroprotective allopregnanolone analogue

Targeting amyloid binding alcohol dehydrogenase with frentizole derivatives

Ignyta acquires four oncology R&D assets from Teva Pharmaceutical

Yisheng Biopharma confirms new vaccine for rabies infection will enter human trials

Scioderm begins phase III trial of Zorblisa in patients with epidermolysis bullosa

Janssen acquires XO1

Can-Fite completes development of biomarker blood test for company's drugs

Heron Therapeutics reports data from phase I study of HTX-011

Amicus Therapeutics reports on meetings with EMA and FDA over migalastat

FDA awards orphan drug designation to Selten's SPI-026 for PAH

Actelion presents new antimalarials

University of Utah describes KDM1A inhibitors

Piramal develops FFAR1 agonists

Purdue Pharma presents new sodium Nav1.7 channel blockers

Evotec and Sanofi establish major strategic alliance

Anthera receives Cystic Fibrosis Foundation Therapeutics award to develop Sollpura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...